The Melanoma Genomics Managing Your Risk Study randomised controlled trial: statistical analysis plan
- PMID: 32605576
- PMCID: PMC7329549
- DOI: 10.1186/s13063-020-04351-w
The Melanoma Genomics Managing Your Risk Study randomised controlled trial: statistical analysis plan
Abstract
Background: The Melanoma Genomics Managing Your Risk Study is a randomised controlled trial that aims to evaluate the efficacy of providing information on personal genomic risk of melanoma in reducing ultraviolet radiation (UV) exposure, stratified by traditional risk group (low or high phenotypic risk) in the general population. The primary outcome is objectively measured total daily Standard Erythemal Doses at 12 months. Secondary outcomes include UV exposure at specific time periods, self-reported sun protection and skin-examination behaviours, psychosocial outcomes, and ethical considerations surrounding offering genomic testing at a population level. A within-trial and modelled economic evaluation will be undertaken from an Australian health system perspective to assess the cost-effectiveness of the intervention.
Objective: To publish the pre-determined statistical analysis plan (SAP) before database lock and the start of analysis.
Methods: This SAP describes the data synthesis, analysis principles and statistical procedures for analysing the outcomes from this trial. The SAP was approved after closure of recruitment and before completion of patient follow-up. It outlines the planned primary analyses and a range of subgroup and sensitivity analyses. Health economic outcomes are not included in this plan but will be analysed separately. The SAP will be adhered to for the final data analysis of this trial to avoid potential analysis bias that may arise from knowledge of the outcome data.
Results: This SAP is consistent with best practice and should enable transparent reporting.
Conclusion: This SAP has been developed for the Melanoma Genomics Managing Your Risk Study and will be followed to ensure high-quality standards of internal validity and to minimise analysis bias.
Trial registration: Prospectively registered with the Australian New Zealand Clinical Trials Registry, ID: ACTR N12617000691347 . Registered on 15 May 2017.
Keywords: Behaviours; Bioethics; Early detection; Genomic risk; Melanoma; Prevention; Psycho-oncology; Randomised controlled trial; Sun exposure; Sun protection.
Conflict of interest statement
The authors declare that they have no competing interests.
Similar articles
-
The melanoma genomics managing your risk study: A protocol for a randomized controlled trial evaluating the impact of personal genomic risk information on skin cancer prevention behaviors.Contemp Clin Trials. 2018 Jul;70:106-116. doi: 10.1016/j.cct.2018.05.014. Epub 2018 May 23. Contemp Clin Trials. 2018. PMID: 29802966 Clinical Trial.
-
Whole brain radiotherapy (WBRT) after local treatment of brain metastases in melanoma patients: Statistical Analysis Plan.Trials. 2019 Aug 5;20(1):477. doi: 10.1186/s13063-019-3555-5. Trials. 2019. PMID: 31382986 Free PMC article. Clinical Trial.
-
Can patient-led surveillance detect subsequent new primary or recurrent melanomas and reduce the need for routinely scheduled follow up? Statistical analysis plan for the MEL-SELF randomised controlled trial.Contemp Clin Trials. 2022 Jun;117:106761. doi: 10.1016/j.cct.2022.106761. Epub 2022 Apr 16. Contemp Clin Trials. 2022. PMID: 35439647 Clinical Trial.
-
The Australasian Resuscitation in Sepsis Evaluation (ARISE) trial statistical analysis plan.Crit Care Resusc. 2013 Sep;15(3):162-71. Crit Care Resusc. 2013. PMID: 23944201 Review.
-
National health strategies to reduce sun exposure in Australia and the United States.J Long Term Eff Med Implants. 2004;14(3):215-24. doi: 10.1615/jlongtermeffmedimplants.v14.i3.60. J Long Term Eff Med Implants. 2004. PMID: 15301665 Review.
Cited by
-
Feasibility and acceptability of a personalised primary prevention strategy for women and men at high risk of breast and prostate cancer: the 3PC study protocol for a pilot randomised controlled trial.BMJ Open. 2025 Feb 17;15(2):e085255. doi: 10.1136/bmjopen-2024-085255. BMJ Open. 2025. PMID: 39961712 Free PMC article.
-
Motivations and Barriers to Participation in a Randomized Trial on Melanoma Genomic Risk: A Mixed-Methods Analysis.J Pers Med. 2022 Oct 12;12(10):1704. doi: 10.3390/jpm12101704. J Pers Med. 2022. PMID: 36294843 Free PMC article.
-
Communicating Personal Melanoma Polygenic Risk Information: Participants' Experiences of Genetic Counseling in a Community-Based Study.J Pers Med. 2022 Sep 26;12(10):1581. doi: 10.3390/jpm12101581. J Pers Med. 2022. PMID: 36294720 Free PMC article.
-
Impact of personal genomic risk information on melanoma prevention behaviors and psychological outcomes: a randomized controlled trial.Genet Med. 2021 Dec;23(12):2394-2403. doi: 10.1038/s41436-021-01292-w. Epub 2021 Aug 12. Genet Med. 2021. PMID: 34385669 Free PMC article. Clinical Trial.
-
Cross-Cultural Adaptation and Validation of a French Version of the Genetic Counseling Satisfaction Scale (GCSS) as an Outcome Measure of Genetic Counseling for Hereditary Breast and Ovarian Cancer.Healthcare (Basel). 2021 Sep 2;9(9):1145. doi: 10.3390/healthcare9091145. Healthcare (Basel). 2021. PMID: 34574919 Free PMC article.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous